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Congenital peribronchial myoﬁbroblastic tumor (CPMT) is a rare entity recognized in the WHO classi-
ﬁcation of pulmonary neoplasms. According to available literature, it is a benign tumor with a high
mortality rate exceeding 50%. It is partially attributed to polyhydramnios, hydrops, prematurity, respi-
ratory distress or adverse surgical outcomes due to intraoperative bleeding. Herein we present a case of
congenital peribronchial myoﬁbroblastic tumor in a premature male infant who was born at 31 weeks
gestation due to polyhydramnios and premature rupture of membranes. Soon after birth, he required
intubation due to worsening respiratory distress. Imaging demonstrated a large right chest mass causing
mediastinal shift. Surgical intervention was attempted, which was challenging due to intraoperative
bleeding and tumor retraction. The patient expired soon after the surgery. Hence, in this report we would
like to share our experience with this difﬁcult diagnosis and treatment of this rare tumor.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Case report
A 27-year-old primigravida female at 31 weeks gestational age
and previously uncomplicated pregnancy presented with prema-
ture rupture of membranes. Ultrasonogram demonstrated an in-
trauterine gestation with polyhydramnios and a fetus with a large
solid and cystic mass in the right chest. After transfer to a tertiary
care facility, a male infant weighting 2060 g was delivered vaginally
with Apgar scores of 2 at 1 min, 3 at 5 min and 7 at 10 min. He
required intubation with high frequency oscillator soon after the
delivery. He was given surfactant to help with respirations. A chest
CT scan demonstrated a homogenous round soft tissue density in
the right hemithorax with a few small cystic spaces (Fig. 1A),
compatible with a diagnosis of congenital pulmonary airway mal-
formation (CPAM).
Due to mass effect leading to progressive collapse of the left
lung, urgent resection of the mass was pursued on the 2nd day of
life. Right posterior lateral thoracotomy was performed with intent
to perform a left lung lobectomy. Surgical intervention proved to beu, jjedrzkiewicz@gmail.com
c. This is an open access article undechallenging. The tumor invaded the right mainstem bronchus and
gave the bronchus the character of thin glass. The surgeons
retracted the lung to provide exposure of the hilum and the
mainstem bronchus completely fractured off the trachea. The tu-
mor itself appeared to be growing into the hilum and after frac-
turing the bronchus through what appeared to be the tumor bed,
the surgeon was forced to place a Satinsky clamp across the hilum.
Moreover, a tear of the superior pulmonary vein back into the
atrium was noted. To control the bleeding and the airways, an
emergency completion pneumonectomy was performed. A pedi-
atric cardiac surgeon was also involved to prevent injury to the
pericardium. Unfortunately, the contralateral lung, which was
suspected to be hypoplastic on antenatal ultrasound, proved to be
insufﬁcient to support the child. After completion of the procedure
the child’s vital signs were heart rate of 130 bpm, blood pressure of
55/25 mmHg and oxygen saturation of 53%. The child was moved to
the intensive care unit and required respiratory and vascular sup-
port. The patient passed away approximately 36 h after the oper-
ation due to inadequate pulmonary reserve.
Pathologic examination revealed a grossly trabeculated solid
mass without a cystic component measuring 5.3  4.5  3.4 cm
(Fig. 1B). On microscopy, the mass partially involved all three lung
lobes, particularly at the bronchovascular margins. No hemorrhage
or necrosis was identiﬁed. The tumor cells had uniform spindler the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A) Contrast CT of the chest, showing a large mostly solid and partially cystic right pulmonary mass; B) Gross photograph of the tumor showing trabecular solid cut surfaces.
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and pink cytoplasm. They grew predominantly in broad fascicles,
replacing normal lung parenchyma and abutting normal structures
including bronchi and vessels (Fig. 2AeD). Briskmitotic activity was
present. The tumor cells were positive for smooth muscle actin,
CD34, calponin and bcl2 immunohistochemical stains, supporting
myoﬁbroblastic differentiation (Fig. 2E and F). The AE1.3 cytoker-
atin cocktail (an epithelial marker) immunohistochemical stain is
usually positive in the epithelial component of pleuropulmonary
blastoma and CPAM but was negative in this case. The desmin
(a muscle marker) immunohistochemical stain was also negative,
ruling out leiomyosarcoma. The Ki-67 proliferation index was
approximately 10%, which was consistent with a mitotically active
tumor. Fluorescent in situ hybridization for the ETV6 rearrange-
ment using a break apart probe was negative excluding congenital
ﬁbrosarcoma (congenital ﬁbrosarcoma typically harbors an ETV6-
NTRK3 gene fusion). Additionally, a Formalin-Fixed Parafﬁn-
Embedded (FFPE) Molecular Inversion Probe Array was performed
using the Affymetrix OncoScan FFPE Assay. A 777 Kb deletion atFig. 2. A) Congenital peribronchial myoﬁbroblastic tumor at low power, H and E stain 2;
larger bronchus, H and E stain 10; D) Neoplastic cells on high power, H and E 100; E)
immunohistochemical stain, 40.2q21.1, Chr2: 130,701,189e131,478,017 (hg19) was identiﬁed in the
tumor tissue as well as in normal lung tissue. This deletion overlaps
with a database of the Genomic Variant Region and therefore, this
copy number change was predicted to be most likely constitutional
or benign. Overall, the morphologic assessment and immunohis-
tochemical stains supported a diagnosis of congenital peribronchial
myoﬁbroblastic tumor.
2. Discussion
CPMT is a rare entity recognized in the WHO classiﬁcation of
pulmonary neoplasms of fetuses and infants. Only 23 reported
cases are found in the literature (Fig. 3) [1]. Usually, this tumor
presents with non-immune hydrops, polyhydramnios and prema-
ture rupture of membranes in the 3rd trimester. On imaging, a large
solid mass in either left or right lung is identiﬁed that may exceed
5 cm [1]. There are no reports describing bilateral lung involvement.
The differential diagnosis includes CPAM, bronchopulmonary
blastoma, congenital ﬁbrosarcoma and leiomyosarcoma. PrenatalB) Tumor tracking along the pulmonary septa, H and E stain 10; C) Tumor abutting a
Positive vimentin immunohistochemical stain, 40; F) Positive smooth muscle actin
Fig. 3. Summary of available publications on CPMT. F e female, M e male, RD e respiratory distress, H e hydrops, PHA e polyhydramnios, PE e pleural effusion, MPB e massive
perioperative bleeding, EM e electron microscopy, IHC e immunohistochemistry, Flow e ﬂow cytometry, Karyo e karyotyping, R e right, L e left [2,5e8,12e27].
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of this neoplasm. Most reported cases were diagnosed during
pathologic assessment with an aid of numerous adjunct studies
including immunohistochemistry, electron microscopy and ﬂuo-
rescent in situ hybridization.
CPAM is a most commonly encountered congenital pulmonary
mass that may also present with hydrops, polyhydramnios, shift of
the mediastinal structures and respiratory distress. Particularly the
solid variant of CPAM can easily be confusedwith CPMTon imaging.
However, Calvo-Garcia et al. report certain characteristic features of
CPMT on magnetic resonance imaging. CPMT is hypointense on
T2-W and hyperintense on T1-W relatively to the lung parenchyma
with a thin peripheral rim of dark T2 signal [2]. These ﬁndings are
not typical for solid type CPAM and these features are suggestive of
a diagnosis of CPMT. Of note, the symptomatic patients with CPAM
are usually treated by surgical resection [3].
According to the scant available literature, CPMT is a benign
tumor and several successful resections have led to no evidence of
metastasis or recurrences [4]. Unfortunately, the mortality rate is
really high, exceeding 50% [1]. The large pulmonary mass most
likely causes aberrant development of the normal respiratory pa-
renchyma due to compression and shift of the mediastinal struc-
tures. Overall, surgical intervention is usually deemed to be
necessary to alleviate mediastinal compression but the surgical
outcomes are often poor due to reduced respiratory function [5].
Therefore, delivery by ex utero intrapartum treatment and utiliza-
tion of extracorporeal membrane oxygenation could be of clinical
consideration [2,6]. Means to support respiratory function should
be prepared because severe respiratory distress is usually antici-
pated in these cases.The resection of a bulky pulmonary mass in a child with respi-
ratory insufﬁciency is a risky procedure. CPMT has a tendency to
grow adjacent to large vessels and bronchi, which was seen grossly
and conﬁrmed microscopically in the current case. This tendency
most likely caused these structures to be fragile during surgical
manipulation. This probably led to the tear in the superior pulmo-
nary vein and fracture of the mainstem bronchus from the trachea
in the current case. Therefore, more extensive surgery with an
emergent complete right pneumonectomy was attempted to save
the child. This surgerywas performed on an emergent basis without
appropriate preparation for extracorporeal membrane oxygenation
placement or lung transplantation. Massive perioperative bleeding
and intraoperative death have also been reported as complications
of CPMT resection [5,7,8]. Among the reported cases, patients with a
diagnosis of a pulmonary mass prior to the development of severe
hydrops and polyhydramnios treated with surgical resection had a
tendency to have a better outcome (Fig. 3). More cases are needed to
make more deﬁnitive conclusions about best practices for man-
agement and the prognosis of patients with CPMT.
Overall, a prenatal diagnosis of a large pulmonary mass should
trigger a referral to a tertiary care center andmore extensive clinical
work-up. Although some of the patients may choose to pursue an
elective abortion, surgical resection may provide a successful
treatment option (Fig. 3). Since CPMT is usually diagnosed in the
3rd trimester, the treatment may include earlier induction of de-
livery in order to provide the necessary interventions, antenatal
corticosteroid therapy to enhance lung maturation or an open fetal
surgery for tumor resection [5].
Perhaps as we expand our understanding of this rare neoplasm
wemight be able to make the diagnosis sooner and to have a better
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standing of this tumor, we attempted to identify its driving mo-
lecular mutation. We have performed FFPE array analysis of this
tumor, which to our knowledge has not been previously reported.
We found a small deletion in the 2q21.1 region, which was deter-
mined to be constitutional as it was also present in the surrounding
normal lung tissue uninvolved by the tumor. This deletion harbors
at least 18 genes including RAB6C and PTPN18. Of note, RAB6C is a
member of the RAS oncogene family and PTPN18 gene is a func-
tional protein-tyrosine phosphatase gene [9e11]. Although, we do
not think that this is a driving molecular mutation for CPMT, the
link between constitutional deletion of 2q21.1 region and CPMT has
not been previously described in the literature. Additional studies
are needed to increase our understanding of the molecular mech-
anisms underlying this neoplasm.References
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